MANAGEMENT OF ENDOCRINE DISEASE

Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia

Anjana Radhakutty1,2 and Morton G Burt1,2

1 College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia, 2 Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia, and 3 Department of Diabetes and Endocrinology, Lyell Mc Ewin Hospital, Adelaide, South Australia, Australia

Abstract

Glucocorticoids are frequently prescribed to patients with a wide range of inflammatory and autoimmune diseases. The semi-synthetic glucocorticoid prednisolone is most commonly prescribed and in two main patterns. Prednisolone is prescribed short term at medium-high doses to treat an acute inflammatory illness or long term at lower doses to attenuate chronic inflammatory disease progression. In hospitalized patients with acute prednisolone-induced hyperglycaemia, there is a distinct circadian pattern of glucose elevation, which occurs predominantly in the afternoon and evening. As a morning dose of isophane insulin has a pharmacokinetic pattern that matches this pattern of glucose elevation, treatment comprising a basal dose of morning isophane insulin in combination with short-acting insulin boluses is generally recommended. However, evidence is lacking that isophane-based basal bolus insulin is more efficacious than other insulin regimens. In outpatients, low-dose prednisolone causes a small increase in post glucose-load glucose concentration but no change in overall glycaemic control as measured by glycosylated haemoglobin. If treatment is indicated, metformin has been shown to be effective and may attenuate other adverse effects of long-term prednisolone therapy. Further studies are necessary in order to identify factors underlying the variability in response to insulin therapy and clinical benefits of treatment in hospitalized patients with prednisolone-induced hyperglycaemia. In outpatients prescribed low-dose prednisolone, the cardiovascular risk associated with postprandial hyperglycaemia and efficacy of hypoglycaemic therapies should be evaluated in future randomized clinical trials.

Invited author’s profile

Associate Professor Morton G Burt is an Endocrinologist working within the Southern Adelaide Diabetes and Endocrine Service, Flinders Medical Centre and Associate Professor, Flinders University in Adelaide, Australia. Associate Professor Burt completed a PhD at the Garvan Institute of Medical Research, Sydney, Australia investigating the effect of glucocorticoids on protein metabolism. Currently, his primary research interests are the effects of glucocorticoid excess on carbohydrate metabolism and cardiovascular risk and management of inpatient hyperglycaemia.
Introduction

The seminal publication in 1949 by Hench et al. reporting that glucocorticoids produced a clinical benefit in patients with rheumatoid arthritis changed the outlook for patients with an inflammatory illness (1). One year later, Hench was awarded the Nobel Prize in Physiology or Medicine along with Edward Jenner and Thadeus Reichstein, who first identified the endogenous glucocorticoid cortisol (2). Glucocorticoids are now recognized to be potent anti-inflammatory agents that modulate many components of the inflammatory cascade via genomic and non-genomic mechanisms (3). Despite the development of a range of other pharmaceutical and biologic agents that reduce inflammation, glucocorticoids remain a critical part of the therapeutic armamentarium for a wide range of inflammatory and autoimmune diseases and the prevalence of glucocorticoid use is increasing (4).

Early studies reported glucocorticoid therapy can increase blood glucose concentration (5). However, almost 70 years after their first use the indications for treatment of glucocorticoid-induced hyperglycaemia and optimum therapeutic approach remain unclear. Management of this large group of patients is dependent on extrapolated data from other clinical scenarios combined with an understanding of the pharmacokinetics and pharmacodynamics of glucocorticoids and hypoglycaemic agents.

Glucocorticoids are most commonly prescribed as the semi-synthetic formulation prednisolone (or prednisone in some parts of the world), which is usually administered as a single morning dose (6, 7, 8). Prednisolone therapy is usually prescribed in two main patterns. It can be prescribed short-term in medium-high doses to treat an acute inflammatory illness such as an exacerbation of obstructive lung disease, often in the hospital setting. Prednisolone is also prescribed long term at lower doses, usually less than 10 mg/day, to attenuate chronic inflammatory disease progression (6, 9). Similar glucocorticoid doses are also prescribed to prevent rejection after solid organ transplant and in patients needing glucocorticoid replacement therapy.

This manuscript will first briefly discuss the metabolic pathways that are affected by glucocorticoids and then review the indications for and efficacy and safety of treatment for hyperglycaemia in (1) hospitalized patients on moderate to high dose prednisolone and (2) outpatients on long-term therapy with lower prednisolone doses. Other clinical scenarios will also be briefly considered. We selected studies to cite in this manuscript after searching PubMed for glucocorticoids AND diabetes, glucocorticoids AND hyperglycaemia and glucocorticoids AND a range of glucose-lowering therapies. Additional articles were selected from our knowledge of the topic. We have tried to limit recommendations to those supported by the literature or to articulate where evidence is lacking.

Mechanisms of glucocorticoid-induced hyperglycaemia

Glucocorticoid-induced hyperglycaemia is the result of impairment of multiple pathways affecting carbohydrate metabolism. Glucocorticoids induce peripheral insulin resistance, which predominantly reflects insulin action in skeletal muscle (10, 11). At higher doses glucocorticoids impair oxidative and non-oxidative glucose disposal, whereas in patients on long-term low-dose prednisolone non-oxidative glucose disposal is predominantly reduced (11, 12). Glucocorticoids reduce glycogen synthase activity in skeletal muscle, which will contribute to a reduction in peripheral non-oxidative glucose disposal (13).

Other aspects of carbohydrate metabolism are also affected. Glucocorticoids cause hepatic insulin resistance resulting in increased hepatic glucose output, even during long-term low-dose prednisolone therapy (10, 12, 14). Acutely glucocorticoids also reduce insulin secretion, but insulin secretion is not reduced in patients on long-term low-dose prednisolone (12, 15, 16). An acute reduction in incretin-induced insulin secretion is likely to contribute to the observed reduction in insulin secretion with glucocorticoids (17).

Acute moderate-to-high-dose prednisolone therapy

How common is prednisolone-induced hyperglycaemia?

Glucocorticoids are prescribed short term in moderate-to-high doses to treat exacerbations of a range of inflammatory illnesses including those of the lungs, gastrointestinal tract, nervous system, joints, kidneys and skin. Glucocorticoids cause a greater increase in blood glucose levels in patients with known diabetes (18, 19). However, 50–70% of hospitalized patients without known diabetes prescribed moderate-to-high glucocorticoid doses also develop hyperglycaemia (8, 18, 20). Differences in patient populations will contribute to variability in the prevalence of hyperglycaemia. In
hospitized patients known diabetes, a longer duration of glucocorticoid therapy, an elevated C-reactive protein and older age have been associated with a greater prevalence and/or severity of hyperglycaemia (8, 18, 20). Abdominal adiposity and a family history of diabetes have also been associated with an increased prevalence of glucocorticoid-induced hyperglycaemia (21, 22). Higher glucocorticoid doses cause a greater degree of insulin resistance and are associated with a greater need for hypoglycaemic therapy and will also influence the prevalence of hyperglycaemia (23, 24).

Is treating hyperglycaemia during acute prednisolone therapy important?

In hospitalized patients, the primary aim of treatment of hyperglycaemia is to prevent any potential excess in morbidity and mortality secondary to glucose elevation during treatment and recovery from an acute illness or surgical procedure (25). There is little direct evidence that treating prednisolone-induced hyperglycaemia reduces morbidity or mortality. In patients with pneumonia treated with prednisone, differences in glucose concentration were not associated with time to clinical stability (26). However, glucocorticoids are a common cause of new hyperglycaemia in hospitalized patients, and new hyperglycaemia is associated with a much greater risk of mortality than chronic hyperglycaemia (27). Moreover, there is evidence that treating inpatient hyperglycaemia reduces morbidity in other clinical scenarios (28). Current guidelines recommend screening all hospitalized patients prescribed glucocorticoids for hyperglycaemia by point of care blood glucose level monitoring for at least 48 h and treatment of those with hyperglycaemia (25).

The glucose threshold at which hypoglycaemic treatment should be started is uncertain. Continuous glucose monitoring of non-diabetic hospitalized patients taking prednisolone demonstrates that although in many patients glucose increases to above 10 mmol/L, it usually stays above this threshold for only a few hours and mean glucose in these patients was 7.7 mmol/L (18). Although there are plausible mechanisms by which short-term hyperglycaemia might increase morbidity and mortality, such as inducing endothelial dysfunction and oxidative stress (29), data on major clinical endpoints are lacking. In our study, the inclusion criteria for hypoglycaemic therapy were one blood glucose level above 15 mmol/L or two blood glucose levels above 10 mmol/L within 24 h, to ensure subjects had either marked or sustained hyperglycaemia (30).

What therapy should be used to treat acute prednisolone-induced hyperglycaemia?

As the aim of glucose-lowering therapy in hospitalized patients is to rapidly control glucose elevations to improve patient outcomes, the Endocrine Society Clinical Practice Guidelines recommend that glucocorticoid-induced hyperglycaemia in hospital should be treated with subcutaneous basal bolus insulin or a continuous insulin infusion if there is severe or persistent hyperglycaemia (25). The rapid onset of action, flexibility in dosing and lack of dose ceiling makes subcutaneous basal bolus insulin a good choice in patients with acute hyperglycaemia on glucocorticoids. As many patients have elevated glucose levels on a standard hospital basal bolus insulin protocol, a specific protocol for prednisolone-induced hyperglycaemia may be required (31). Similar to results in other hyperglycaemic patients, an insulin sliding scale is not recommended as it is less effective than subcutaneous basal bolus insulin in glucocorticoid-treated patients (32, 33, 34).

There are limited data on the use of other hypoglycaemic agents in the management of glucocorticoid-induced hyperglycaemia in the hospital setting. It has been recommended that these agents be discontinued in hospital when initiating insulin therapy (25), but this decision should be individualized. The efficacy of other hypoglycaemic agents will be discussed in the section on long-term glucocorticoid treatment.

Pharmacokinetics of insulin therapy for prednisolone-induced hyperglycaemia

Studies characterizing the circadian pattern of glucose elevation induced by prednisolone potentially inform the pharmacokinetic profile of insulin therapy for prednisolone-induced hyperglycaemia (18, 19). Following an oral morning dose of prednisolone the glucose concentration peaks 8 h later at about 16:00 h (Fig. 1) (18). This pattern is similar to the timing of prednisolone’s peak anti-inflammatory action (35). In patients without known diabetes glucose returns to normal by midnight with little effect on overnight glucose concentration (18). In patients with diabetes, glucose elevations are greater, but the circadian pattern of hyperglycaemia is similar (18, 19).

These studies support recommendations to use insulin isophane alone or in combination with short-acting insulin to treat glucocorticoid-induced hyperglycaemia. When administered as a single morning dose, insulin isophane’s onset of action, peak effect and duration
of action closely match the pattern of prednisolone-induced hyperglycaemia (36). Thus, insulin isophane has the potential to better treat daytime hyperglycaemia and avoid overnight hypoglycaemia arising from longer-acting basal insulin preparations.

However, the small numbers of clinical studies performed have not conclusively demonstrated a benefit of insulin isophane in patients with glucocorticoid-induced hyperglycaemia (Table 1). A retrospective study comparing insulin isophane and insulin glargine as the basal insulin in hospitalized patients with hyperglycaemia on prednisolone was promising as isophane-treated patients required 20% less insulin to achieve the same degree of glycaemic control (37). Another study reported prescribing additional isophane insulin as well as the standard hospital subcutaneous basal bolus insulin regimen resulted in a lower mean glucose concentration on the third day of insulin therapy (38). However, isophane-treated patients’ daily insulin dose was 16% higher than controls in this study and optimal assessment of the effect of different pharmacokinetic insulin profiles per se requires matching of insulin doses.

Two complementary randomized controlled studies have compared matched doses of isophane-based and glargine-based basal bolus insulin in patients on glucocorticoids (30, 39). In both studies, 50% of the daily dose was administered as basal insulin and 50% as short-acting insulin with meals (30, 39). Ruiz de Adana et al. reported that in patients with type 2 diabetes and respiratory disease treated with methylprednisolone or deflazacort, there was no significant difference in glucose control between patients randomized to glargine- or isophane-based basal bolus insulin (39). Similarly, we reported no difference in mean glucose or hypoglycaemia in patients with hyperglycaemia with or without known diabetes while taking short-term prednisolone who were randomized to insulin glargine and insulin aspart vs insulin isophane and insulin aspart (30).

We analysed our study to understand why there was no significant difference between isophane- and glargine-treated patients (30). Firstly, despite body weight-based insulin dosing, there was marked variability in the therapeutic response in both treatment groups. Figure 2 shows that there were patients on both insulin regimens who were within a target glucose range of 4–10 mmol/L nearly all the time and other patients who were almost always outside the target range. BMI, mean glucose on the day before starting insulin and prior insulin treatment were independent predictors of response to insulin, but only explained 48% of the variability in time outside the target glucose range. Secondly, patients were usually discharged rapidly from the hospital and insulin pharmacokinetics is likely to be more important when the insulin doses have been optimized.

### Table 1  Studies comparing isophane insulin-based regimens to other therapeutic regimens in patients on glucocorticoids.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Glucocorticoid</th>
<th>Isophane group</th>
<th>Comparator</th>
<th>Results/comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>(37)</td>
<td>Retrospective</td>
<td>Prednisone</td>
<td>Isophane and short-acting insulin, glargine and lispro</td>
<td>Glargine and short-acting insulin, glargine and lispro</td>
<td>No difference in glycaemic control</td>
</tr>
<tr>
<td>(38)</td>
<td>Prospective RCT</td>
<td>Any</td>
<td>Isophane and short-acting insulin, glargine and lispro</td>
<td>Glargine and short-acting insulin, glargine and lispro</td>
<td>Isophane group used 20% less insulin</td>
</tr>
<tr>
<td>(39)</td>
<td>Prospective RCT</td>
<td>Methylprednisolone or deflazacort</td>
<td>Isophane and glulisine and insulin aspart</td>
<td>Glargine and glulisine</td>
<td>No difference in glycaemic control</td>
</tr>
<tr>
<td>(30)</td>
<td>Prospective RCT</td>
<td>Prednisolone</td>
<td>Isophane and glulisine and insulin aspart</td>
<td>Glargine and glulisine</td>
<td>Isophane group had lower BGL on Day 3</td>
</tr>
</tbody>
</table>

BGL, blood glucose level; RCT, randomized controlled trial.
What insulin dose should be prescribed for prednisolone-induced hyperglycaemia in hospital?

The Endocrine Society Clinical Practice Guidelines recommend a starting daily insulin dose of 0.3–0.5 units/kg body weight in hospitalized patients with hyperglycaemia on glucocorticoids (25). Others have recommended a single daily dose of isophane based on weight and prednisone dose, with the daily insulin dose increased by 0.1 units/kg for every 10 mg of prednisone prescribed, up to a maximum of 0.4 units/kg (36). However, the evidence for these recommendations is limited. In our study insulin-naïve patients were prescribed a starting daily insulin dose of 0.5 units/kg plus supplemental insulin for hyperglycaemia, resulting in a daily insulin dose of more than 0.6 units/kg (30). There were no episodes of severe hypoglycaemia and glucose measured with a continuous glucose monitoring system was below 4 mmol/L for only 2% of the day. Others have also reported that the risk of hypoglycaemia with similar insulin doses is low in this patient group (39). We recommend that in hospitalized patients, where the aim is rapid glycaemic control, most patients who have not previously been on insulin should be prescribed an initial daily dose of 0.5 units/kg. Patients at increased risk of hypoglycaemia should be started on a lower daily insulin dose, such as 0.3–0.4 units/kg.

Insulin dosing requirements in patients with type 2 diabetes who are already taking insulin are even less studied. In our study, we increased daily insulin dose by 30% or to 0.5 units/kg, whichever was greater (30). However, during continuous glucose monitoring, the blood glucose level was above 10 mmol/L for 70% of the day. Therefore, most patients with similar clinical characteristics to those in our study will require >30% increase in insulin to achieve good glycaemic control.

Finally, patients with glucocorticoid-induced hyperglycaemia that do not initially reach treatment targets require greater increases in the insulin dose than in other clinical scenarios. Despite a 19% increase in daily insulin dose over 48 h, we found no significant change in glycaemic control. In contrast, an increase in mean daily insulin dose of 48% over the same time period did reduce mean daily blood glucose level (38). Supplemental insulin doses should also be higher in glucocorticoid-treated patients, consistent with guidelines for insulin-resistant patients (25).

Hospital discharge planning

It is critical that hospitalized patients with prednisolone-induced hyperglycaemia are given advice regarding reducing insulin doses as prednisolone is tapered or stopped to prevent hypoglycaemia. If high-dose prednisolone is stopped abruptly, and assuming glycaemic control has previously been good, patients should be advised to return to their usual treatment before starting prednisolone. Although supporting evidence is lacking, it has been recommended that a reduction in prednisolone dose should be associated with a proportionate reduction in insulin doses (36).

Outpatients with high-dose prednisolone-induced hyperglycaemia

There are limited data informing how to manage outpatients with hyperglycaemia on high-dose prednisolone. However, if insulin is prescribed, practically once-daily treatment with a morning dose of isophane insulin is easier for patients to learn to administer than multiple daily insulin injections. We recommend starting with a lower daily insulin dose of 0.3–0.4 units/kg as the support to manage severe hypoglycaemia in the community might not be as prompt as in hospital. The efficacy of other hypoglycaemic agents will be reviewed in the section on chronic prednisolone use.
Other glucocorticoid regimens

Yates et al. reported that dividing prednisolone into two daily doses attenuates the daytime peak in glucose and reduced mean daily glucose, but patients have a higher glucose concentration overnight (40). Consequently patients on twice-daily prednisolone with hyperglycaemia are probably best treated with a longer-acting basal insulin with a flatter insulin profile, such as glargine or detemir, alone or in combination with a short-acting insulin if there are postprandial glucose elevations. Dexamethasone has a longer serum half-life and duration of action than prednisolone, but whether it causes a glucose peak is not clearly documented. However, based on the current understanding of its pharmacokinetics, dexamethasone-induced hyperglycaemia should also be treated with a longer-acting basal insulin. The doses of insulin required for patients treated with dexamethasone (and other glucocorticoids) have not been well studied, but should take into account its greater glucocorticoid potency compared to prednisolone (41).

Summary

The aim of treating prednisolone-induced hyperglycaemia in hospitalized patients is to rapidly control glucose elevations to potentially reduce associated morbidity and mortality. Based on the circadian pattern of glucose elevation induced by prednisolone, hyperglycaemia should be treated with isophane insulin alone or in combination with short-acting insulin. However, the superiority of this approach over other insulin regimens has not been clearly established. Most patients with prednisolone-induced hyperglycaemia who are not already taking insulin should be prescribed a starting daily insulin dose of 0.5 units/kg. Patients on twice daily prednisolone or longer-acting glucocorticoids should be prescribed a basal insulin with a longer duration of action.

Chronic low-dose glucocorticoid therapy

How commonly is low-dose prednisolone prescribed?

Recent studies report the prevalence of long-term oral glucocorticoid use in the general population of the United Kingdom and United States is 0.75–1.2% (6, 7). In clinical practice, glucocorticoids, usually prednisolone, are most commonly taken by patients with obstructive lung disease and inflammatory rheumatologic disorders, but are also prescribed for a wide range of other chronic inflammatory illnesses including gastrointestinal, dermatology, neurologic and renal disorders (6). The prevalence of glucocorticoid use increases with age, with up to 2.5% of adults aged >60 years prescribed long-term glucocorticoids (7). Consequently a large number of adults with other risk factors for diabetes (older age and an inflammatory illness) are prescribed chronic glucocorticoid therapy.

Does long-term low-dose prednisolone increase blood glucose?

As the effects of glucocorticoids on blood glucose concentration are dose dependent, (23) there has been uncertainty regarding the effects of chronic low-dose glucocorticoid therapy on blood glucose concentration. Most patients with inflammatory rheumatologic disease are prescribed daily prednisolone doses below 10 mg (24). However, while these doses are much lower than those used acutely, they are substantially higher than average endogenous glucocorticoid production, which equates to about 3 mg prednisolone per day (42).

We reported that patients on long-term low-dose prednisolone (4–10 mg/day) for inflammatory rheumatologic disease had no increase in fasting glucose concentration or glycosylated haemoglobin (HbA1c), but average glucose after a glucose load was increased by 1.2 mmol/L compared with patients with inflammatory arthritis who were not taking prednisolone (43). These results might be expected as low-dose prednisolone causes insulin resistance in liver and skeletal muscle (12, 44). However, they contrast another study reported that fasting and post glucose load glucose concentrations and insulin sensitivity in patients with rheumatoid arthritis were not affected by a similar prednisolone dose (45). This study did report that daily and cumulative prednisolone dose were associated with risk of diabetes (45). The patients in the study by Hoes et al. on prednisolone were 12 years younger and had a BMI that was 4 kg/m² less than prednisolone-treated patients in our study (43, 45). These differences in patient characteristics may influence susceptibility to the adverse metabolic effects of prednisolone. On balance, long-term prednisolone therapy at daily doses below 10 mg causes mild postprandial hyperglycaemia, but minimal change in fasting glucose or HbA1c. The effects appear to be greater in older and overweight patients and in those with a higher cumulative prednisolone dose.
How should you screen for diabetes in patients on long-term prednisolone?

In the general community, fasting glucose, an oral glucose tolerance test and HbA1c are all considered equally appropriate screening tests for type 2 diabetes (46). However, as prednisolone predominantly increases postprandial glucose, fasting glucose has low sensitivity to diagnose diabetes in this patient group. In patients with inflammatory rheumatologic disease, there is marked overlap in fasting glucose concentrations in patients with and without diabetes on long-term prednisolone, but much less so in patients not taking prednisolone (Fig. 3) (43). Average HbA1c is not increased, and it also has low sensitivity to diagnose diabetes in patients on long-term prednisolone (43). Consequently, the 2-h plasma glucose concentration during an oral glucose tolerance test identifies more cases of diabetes in patients on long-term prednisolone than fasting glucose or HbA1c (43). Some authors have proposed that a late afternoon random glucose should be used to screen for diabetes in patients taking prednisolone (41, 47). However, studies are needed to demonstrate the superiority of this approach.

Is diagnosing prednisolone-induced diabetes important?

The primary aim of treating hyperglycaemia in patients on long-term prednisolone is to reduce microvascular and macrovascular complications of diabetes. There are no data reporting rates of microvascular complications in patients on long-term prednisolone. HbA1c is a strong predictor of microvascular complications and average HbA1c is not increased by low-dose prednisolone (43, 48). However, other factors such as postprandial hyperglycaemia and glycaemic variability may also play an important role (49). Moreover, post-glucose load hyperglycaemia is associated with an increased risk of cardiovascular disease at glucose concentrations below the threshold for diabetes (50, 51). As inflammatory diseases per se are associated with increased cardiovascular risk (52), an important question is whether prednisolone-induced insulin resistance and consequent postprandial hyperglycaemia increases cardiovascular risk.

There are no clinical trials of sufficient size and duration to determine the effect of low-dose prednisolone on cardiovascular risk. Therefore, the cardiovascular effects of prednisolone can only be inferred from epidemiologic and mechanistic studies. Epidemiologic studies have reported that higher glucocorticoid doses increase all-cause and cardiovascular mortality (9, 53, 54). Lower daily prednisolone doses below 10mg have been associated with increased mortality in some studies (53, 54), but not in others (9). Moreover, these studies are potentially confounded by indication bias.

Arterial stiffness and endothelial dysfunction are potential mechanisms by which glucocorticoids might increase cardiovascular risk, directly or indirectly via changes in insulin sensitivity and/or glucose levels. Arterial stiffness and endothelial dysfunction are strong predictors of cardiovascular risk, independent of other cardiovascular risk factors (55, 56) and are most strongly associated with post-glucose load glucose concentration (57, 58). Prednisolone reduces pulse wave velocity, the gold-standard measure of arterial stiffness, during an acute flare of an inflammatory illness (59), but in other clinical situations, glucocorticoids do not have a significant effect (60, 61, 62).
Glucocorticoid therapy has been associated with endothelial dysfunction in healthy adults (63), hypopituitar patients (60) and patients with IgA nephropathy (64). In contrast, in patients with inflammatory rheumatologic disease, long-term prednisolone has been reported to have a neutral or beneficial effect on fasting and postprandial endothelial function (16, 62, 65). Plasma asymmetric dimethyl arginine is elevated in patients with rheumatoid arthritis who are not taking prednisolone, but not in patients on long-term low-dose prednisolone (66). If long-term prednisolone lowers the elevated levels of this endogenous nitric oxide synthase inhibitor, it could explain a beneficial effect of prednisolone on endothelial function in patients with inflammatory rheumatologic disease.

In summary, it is not clear to what extent low-dose prednisolone and the consequent minor increase in postprandial glucose increases cardiovascular risk. Moreover, the risks may vary in different patient populations. Pending further information, current thresholds for hypoglycaemic therapy and glycaemic targets should therefore be similar to those used in other clinical scenarios (67).

**How should prednisolone-induced diabetes be treated?**

There are few studies informing how to treat hyperglycaemia in patients taking chronic low-dose prednisolone. Insulin is always a potential therapy, but will not be discussed further in this section. Many studies investigating the efficacy of other therapeutic agents have enrolled patients on moderate-to-high glucocorticoid doses, thereby potentially underestimating the glycaemic benefits in routine clinical practice where lower prednisolone doses are usually prescribed. As such, treatment decisions must be extrapolated from studies in patients with type 2 diabetes, along with an understanding of the pharmacodynamic effects and adverse drug reactions of prednisolone and hypoglycaemic therapy (Table 2). An ideal therapy will improve insulin sensitivity, target postprandial hyperglycaemia, not exacerbate the adverse drug reactions of prednisolone such as weight gain and increased fracture risk and reduce cardiovascular events in these patients who are at high baseline risk.

Metformin is first-line therapy in patients with type 2 diabetes and has a pharmacodynamic and side effect profile that recommends it as a therapeutic option in patients with prednisolone-induced hyperglycaemia. Metformin lowers fasting and postprandial blood glucose by increasing insulin sensitivity in the liver and effects mediated by the gastrointestinal tract (68, 69). In a small randomized controlled trial comprising 29 patients starting a mean daily prednisolone dose of 33 mg, metformin therapy for 4 weeks prevented the rise in plasma glucose associated with prednisone (70). As the effect of glucocorticoids on blood glucose is dose dependent, at lower glucocorticoid doses that are more commonly used long-term, metformin is likely to reduce blood glucose. As metformin does not increase weight and probably reduces cardiovascular and fracture risk (71, 72, 73), it should not exacerbate other adverse effects associated with the underlying disease or long-term prednisolone.

Thiazolidinediones target two of the major metabolic abnormalities induced by glucocorticoids as they improve both hepatic and peripheral insulin sensitivity (74). Troglitazone was reported to be effective, but is now unavailable as it can cause hepatic failure (75). In a small study, pioglitazone improved glycaemic control in prednisone-treated patients after organ transplantation (76). However, pioglitazone is a less attractive therapeutic option in patients on prednisolone as its adverse effects such as weight gain, increased fracture risk and fluid retention mirror and potentially exacerbate the adverse effects of prednisolone (73, 74).

There is limited evidence that insulin secretagogues can be efficacious in patients on long-term glucocorticoids. The sulphonylurea glimepiride improved glycaemic control in three Japanese patients taking prednisolone 20–40 mg/day (77). However, the non-glycaemic effects of sulphonylureas are less favourable than metformin as they induce weight gain, can cause hypoglycaemia, have a neutral effect on fracture risk and uncertain effect on cardiovascular risk (73, 78). Meglitinides require multiple daily doses but have the potential advantages of predominantly affecting postprandial glucose and no weight gain (79). In a small open study, repaglinide provided effective glycaemic control in 14 of 23 patients on low-dose prednisolone combined with other immunosuppressive therapy (80).

Glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors predominantly lower postprandial glucose, suggesting they may be used to treat prednisolone-induced hyperglycaemia. Intravenous exenatide improved blood glucose in healthy subjects taking high-dose prednisolone for 2 days (81). However, apart from case reports (82), longer-term data on the efficacy of GLP-1 agonists in patients taking prednisolone is lacking. Liraglutide has not been studied in patients on prednisolone but its non-glycaemic effects
Table 2  Effects of prednisolone and glucose-lowering treatments on weight, and fracture and cardiovascular risk.

<table>
<thead>
<tr>
<th></th>
<th>Prednisolone</th>
<th>Metformin</th>
<th>Sulphonylureas</th>
<th>Thiazolidinediones</th>
<th>GLP-1 agonists</th>
<th>DPP-4 inhibitors</th>
<th>SGLT2 inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Fracture risk</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↑</td>
<td>↓</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>Cardiovascular risk</td>
<td>↑/1*</td>
<td>↓</td>
<td>↔</td>
<td>↑/1*</td>
<td>↓</td>
<td>↔</td>
<td>↓</td>
</tr>
</tbody>
</table>

*May vary in different patient populations or for different drugs in class (see text for details).
↑, increased; ↓, reduced; ↔, unchanged; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose co-transporter-2.

are favourable as it can cause weight loss and reduce fracture and cardiovascular risk (73, 83). In contrast, some data suggest exenatide may increase fracture risk (73). The DPP-4 inhibitor sitagliptin improved glycaemic control in a retrospective study of subjects on low-dose prednisolone (84), but did not attenuate the postprandial effects of a 30 mg daily prednisolone dose in a prospective randomized controlled trial (85). These contrasting results may reflect the difference in prednisolone dose in the two studies or could reflect potential selection bias in the retrospective study. DPP-4 inhibitors do not exacerbate the side effects of prednisolone.

Finally, sodium-glucose co-transporter-2 (SGLT2) inhibitors also predominantly reduce postprandial glucose in patients with type 2 diabetes. However, dapagliflozin did not improve glycaemic control in patients with type 2 diabetes or hyperglycaemia while taking high dose prednisolone (86). SGLT2 inhibitors reduce weight and cardiovascular mortality in patients with type 2 diabetes, but may increase fracture risk (73, 87).

**Future directions and final conclusions**

After almost 70 years of using glucocorticoids to treat inflammatory disease, there are many unanswered questions regarding how to treat glucocorticoid-induced hyperglycaemia. Identification of factors underlying the variability in response to insulin therapy in hospitalized patients with hyperglycaemia while taking glucocorticoids is needed to inform individualized treatment and improve patient management. In outpatients taking long-term low-dose prednisolone, further understanding of the cardiovascular risk associated with postprandial hyperglycaemia and studies of the effects of hypoglycaemic therapies in patients on lower doses of prednisolone are needed to provide a stronger evidence base to manage this large group of patients. Based on the current limited evidence, we advocate first-line therapy for hyperglycaemia with isophane-based basal bolus insulin regimens in hospitalized patients treated with acute prednisolone and metformin in outpatients taking chronic low-dose prednisolone.

**Declaration of interest**

Dr M G Burt has previously received grant funding from the Novo Nordisk Regional Diabetes Scheme.

**Funding**

Dr A Radhakutty is supported by a National Health Medical Research Council, Australia Postgraduate Research Scholarship.

**References**

1 Hench PS, Kendall EC, Slocumb CH & Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. *Proceedings of the Staff Meetings of the Mayo Clinic* 1949 24 181–197.
2 Kirwan JR, Balint G & Szebenyi B. Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis. *Rheumatology* 1999 38 100–102. ([https://doi.org/10.1093/rheumatology/38.2.100](https://doi.org/10.1093/rheumatology/38.2.100))


19 Yuen KC, McDaniell PA & Riddle MC. Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-


in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007 30 2181–2186. (https://doi.org/10.2337/dc07-0295)


49 Cavallot E Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes, Obesity and Metabolism 2013 15 (Supplement 2) 3–8. (https://doi.org/10.1111/dom.12140)


Received 13 April 2018
Revised version received 17 June 2018
Accepted 6 July 2018